Sources last read
The page
GLP-1 patches and the transdermal delivery record
There is no GLP-1 patch. Every approved semaglutide product is an injection or a tablet, and every approved tirzepatide product is an injection. Nothing goes through skin. The reason is size: the heaviest ingredient FDA has ever approved for delivery through skin weighs 467.6 g/mol. Semaglutide weighs 4,113.58 and tirzepatide 4,813.53.
Source: Drugs@FDA, DailyMed and ClinicalTrials.gov, all searched 2026-08-12
What matters first
Two things complicate that answer, and both are below. Two early trials of semaglutide microneedle patches started in 2026 — but those use tiny needles that pierce the skin, not a stick-on patch. And the patches actually sold online are supplements: a 2026 review found 24 of them, listing plant ingredients like berberine and cinnamon.
Almost everything written about this is written by someone selling a patch, and a page that sells one cannot also report that no approved one exists. So every check below names the database, the search and the day we ran it. Run it again and you will either get the same answer or catch us being wrong.
157 transdermal products on 21 ingredients · Drugs@FDA query products.route:"TRANSDERMAL"
What is approved, and by which route
How a drug is given is not a marketing choice. It is a fixed field in the approval record, and it is the first thing to check when a new format shows up. Both GLP-1 drugs come back with the same short list.
| Molecule | Empirical formula | Molecular weight | Every approved route |
|---|---|---|---|
| Semaglutide | C187H291N45O59 | 4,113.58 g/mol | Subcutaneous injection · Oral tablet |
| Tirzepatide | C225H348N48O68 | 4,813.53 g/mol | Subcutaneous injection |
Everything the FDA has approved for delivery through skin
This is the hardest part of the page to argue with, because it is the complete list rather than a sample. Every product FDA has approved for delivery through skin — 157 applications, 420 product entries — runs on just 21 ingredients. Here they all are, heaviest first, with the two GLP-1 drugs added at the bottom for scale.
| # | Active ingredient | Molecular weight | Delivered through skin in an approved product |
|---|---|---|---|
| 1 | Buprenorphine | 467.6 g/mol | Yes |
| 2 | Donepezil | 379.5 g/mol | Yes |
| 3 | Oxybutynin | 357.5 g/mol | Yes |
| 4 | Norethindrone acetate | 340.5 g/mol | Yes |
| 5 | Fentanyl | 336.5 g/mol | Yes |
| 6 | Norelgestromin | 327.5 g/mol | Yes |
| 7 | Rotigotine | 315.5 g/mol | Yes |
| 8 | Granisetron | 312.4 g/mol | Yes |
| 9 | Levonorgestrel | 312.4 g/mol | Yes |
| 10 | Scopolamine | 303.35 g/mol | Yes |
| 11 | Ethinyl estradiol | 296.4 g/mol | Yes |
| 12 | Testosterone | 288.4 g/mol | Yes |
| 13 | Asenapine | 285.8 g/mol | Yes |
| 14 | Estradiol | 272.4 g/mol | Yes |
| 15 | Rivastigmine | 250.34 g/mol | Yes |
| 16 | Methylphenidate | 233.31 g/mol | Yes |
| 17 | Clonidine | 230.09 g/mol | Yes |
| 18 | Nitroglycerin | 227.09 g/mol | Yes |
| 19 | Selegiline | 187.28 g/mol | Yes |
| 20 | Nicotine | 162.23 g/mol | Yes |
| 21 | Dextroamphetamine | 135.21 g/mol | Yes |
| — | Semaglutide | 4,113.58 g/mol | No approved product |
| — | Tirzepatide | 4,813.53 g/mol | No approved product |
Why the list stops where it does
Every one of those 21 ingredients is small — under 500 g/mol, with Buprenorphine the heaviest at 467.6. Semaglutide is about 8.8 times that, tirzepatide about 10.3 times. Skin scientists have called this the 500 Dalton rule since 2000, on the observation that everything known to cross skin sits under it. It is a pattern rather than a law of physics — but it describes every single product in the table above.
What the oral tablet tells you about the difficulty
There is one useful comparison. Semaglutide is the only GLP-1 with an approved form that is not an injection, and its label shows what that took. The tablet is built with Salcaprozate sodium (SNAC), a helper ingredient whose whole job is getting the peptide across the stomach lining — and even then only about 1% to 2% of the dose reaches the bloodstream. That was a dedicated development program aimed at a wet, absorbent surface. Skin is drier and fussier than the gut, and no stick-on patch carries anything like that helper system.
Marketing claims checked against evidence
These are the claims these products are usually sold on, checked one by one. No seller is named, ranked or linked anywhere on this site — the claim is what is being checked, not the company.
| Claim as marketed | What the evidence shows | Checked against |
|---|---|---|
| A skin patch delivers semaglutide or tirzepatide into the bloodstream. | No approved product does this. Searching Drugs@FDA for every application containing either molecule returns subcutaneous injections and oral tablets only. Searching the same database for every product with a transdermal route returns 157 applications, none of which contains a peptide. | U.S. Food and Drug Administration; DailyMed, U.S. National Library of Medicine |
| A patch is the needle-free way to take a GLP-1 medicine. | The only GLP-1 patches in registered human trials are microneedle arrays, which work by piercing the outer skin layer with a bed of needles. Both are Phase 1 safety and bioavailability studies that began in 2026 and have posted no results. | ClinicalTrials.gov, U.S. National Library of Medicine |
| The patch works the same way the injection does, without the injection. | No published pharmacokinetic data supports an equivalence claim for any adhesive patch. For scale, look at the one approved non-injected route. The oral tablet needs a dedicated absorption enhancer, and even then only about 1% to 2% of the dose gets across the stomach lining. | DailyMed, U.S. National Library of Medicine |
| It is a natural GLP-1 patch, so it is a supplement rather than a drug. | Federal law defines a dietary supplement as a product intended for ingestion. A product worn on the skin does not meet that definition. A 2026 review in Annals of Pharmacotherapy identified 24 transdermal patch products and one gel marketed this way and concluded they are outside the statute. | United States Code, 2023 Edition — via GovInfo; Annals of Pharmacotherapy — via PubMed |
| The ingredients are tested and the product is lab verified. | The same review found that none of these products posted a certificate of analysis. Many omitted the required disclaimer, and many advertised deceptively. The listed ingredients were botanicals and amino acids, most often berberine, glutamine or glutamate, cinnamon and pomegranate. | Annals of Pharmacotherapy — via PubMed |
| Peptides that large can cross skin with the right formulation. | That is an open research question, not a settled capability. The heaviest active ingredient in any approved transdermal product weighs 467.6 g/mol; semaglutide is 4,113.58 and tirzepatide is 4,813.53. Published work on getting semaglutide through skin uses dissolving microneedles. The 2026 study reporting that approach ran on pig skin and a laboratory model, not in people. | PubChem, U.S. National Library of Medicine; DailyMed, U.S. National Library of Medicine; AAPS PharmSciTech — via PubMed |
7Read the full evidence guide
What is actually being tested in people
A flat no would be wrong here. Getting a GLP-1 through skin is a live research program with two registered human trials, both started in 2026. Saying so is the difference between a record and a rebuttal.
| Registry ID | Sponsor | What is being given | Phase and status | Started | Participants |
|---|---|---|---|---|---|
| NCT07673900 | Terrestrial Bio, Inc. | VX-201, registered as a “needle free, shelf-stable, microneedle array patch (MAP) for delivery of semaglutide epi/intra-dermally”, compared against subcutaneous semaglutide | Phase 1 (first-in-human) | 2026-06-15 | 62 |
| NCT07539415 | Daewoong Pharmaceutical Co. LTD. | DWRX5003, registered as a “microneedle patch containing Semaglutide”, against two semaglutide comparators and a placebo microneedle patch | Phase 1 | 2026-05-06 | 72 |
A microneedle array is not the patch being sold
Both studies use a microneedle array: a small bed of needles that punctures the outer layer of skin and drops the drug underneath. That gets past the skin barrier by making holes in it. A sticker that relies on a molecule drifting through skin on its own is a completely different proposition. Both trials are Phase 1 and still recruiting, with no results posted to ClinicalTrials.gov.
In a company announcement, Daewoong said a separate 70-person human pilot measured how much drug reached the blood. That does not show weight-loss efficacy or turn an online sticker into semaglutide. Read the sponsor announcement.
The lab work points the same way. A 2026 study of a dissolving microneedle system for semaglutide tested insertion on pig skin in a lab model. Its authors say stability and loss of potency are still unsolved. Searches for a registered human study of transdermal tirzepatide, transdermal liraglutide or an exenatide patch returned nothing on 2026-08-12 — the exact searches were “transdermal tirzepatide”, “transdermal liraglutide”, “transdermal patch exenatide”.
The patches sold online are a different category of thing
Patches sold as GLP-1 patches are sold as dietary supplements, not drugs, which is how they reach the market without approval. There is a catch, and it is written into the law rather than a matter of opinion: a dietary supplement is legally defined as something you swallow. A patch is worn, not swallowed — so the category these products claim is not open to them.
A 2026 review in Annals of Pharmacotherapy made that argument and counted the market on the way past. It found 24 patch products and one gel, averaging seven plant ingredients each. The usual ones were berberine, glutamine or glutamate, cinnamon and pomegranate.
None posted a certificate of analysis, many were missing the required disclaimer, and many advertised deceptively. That is not a GLP-1 drug. It is a botanical patch borrowing the name of one.
What the ones on sale actually say they contain
We opened every patch listing we could find and copied down what each one states. Two different products turn out to be sold under one name, which is the single most useful thing to know before reading any review.
Berberine stickers · 6 brands
Microneedle patches · 4 brands
Of the 10 listings read on 2026-08-13, only 2 publish an ingredient list at all. On 2026-03-31 the FDA wrote to a seller of one of the microneedle patches and called it an unapproved new drug. The brand-by-brand detail, with each seller’s own wording, is in the patch brand register.
Peptides this size have been tried before
The size argument above is a pattern, not a law. So the fairer test is what happened when drug companies actually tried. 15 human trials have put a peptide into a skin patch, across 6 molecules, going back to 2007.
The closest comparison is teriparatide. It weighs 4,118 g/mol against semaglutide’s 4,113.58 — the same size, as far as skin is concerned. Eli Lilly put it in a patch and ran it against the injection. The injection moved the trial’s main measurement by 7.8; the three patch arms managed 0.63, 0.32 and 1.63.
A different peptide, abaloparatide, got further. Its patch reached about two-thirds of the injection in a 511-person phase 3 that finished in 2021. Neither molecule has an approved skin product today, and nor does any other peptide. The whole record, with the posted numbers, is in the microneedle trial record.
Side effects, and why the safety database is empty
People search for GLP-1 patch side effects expecting the answer that comes with a real medicine. There is no such list, and the reason is worth understanding before you read reassurance into it.
| What was searched | Reports found |
|---|---|
| Any product reported under the name “GLP-1 patch” | 0 |
| The same, spelled without the hyphen | 0 |
| Ledisa, the most-searched patch brand | 0 |
| Oceaura | 0 |
| Buildleaf | 0 |
| Semaglutide, any product — the control | 73,001 |
FAERS holds no report naming any of these patches. That is not a clean safety record — it is the wrong filing cabinet. FAERS is fed by prescribers, pharmacists and drug manufacturers, and a patch bought online has none of them involved. Reports about supplements go to a separate FDA system called CAERS, which collects far fewer reports and depends on someone choosing to file. Silence from a system nobody was reporting into measures the paperwork, not the product.
| System | What it covers | Who files into it | Covers these patches |
|---|---|---|---|
| FAERS | Approved and marketed drugs | Manufacturers, prescribers, pharmacists and the public | No |
| CAERS | Foods, cosmetics and dietary supplements | Voluntary reports from the public and health professionals | Yes |
What a patch can plausibly do to you is mostly a skin question. Adhesives and plant extracts cause rashes and irritation where they sit. That is a real effect and nobody is counting it here.
How people are told to use them
A lot of searches ask where to put a patch and how long to wear it. Here is what the sellers themselves say, reported because it is what they say — not because following it achieves anything.
- Most berberine listings say to wear one patch for up to 8 hours, then throw it away. A few say 8 to 12 hours.
- Placement advice is generally clean, dry, hair-free skin, rotating the spot each day. Upper arm, hip, shoulder and abdomen all appear.
- The microneedle listings differ: at least 4 hours, once or twice a week rather than daily.
- One listing gives a wear time of 8 hours in one place and 24 hours in another, on the same page.
None of that is our instruction, and none of it is a dose. Where you stick a patch cannot fix the problem that the molecule it is named after does not cross skin.
What they cost, and where they are sold
Listed prices run from about $12 to $40 a month for the berberine stickers, and roughly $16 to $77 for the microneedle ones. Amazon carries berberine patches from several brands. We could not check Walmart, CVS or Costco, because all three refused an automated request — so whether they stock any of this is unproven rather than ruled out.
For what the real drugs cost, including which savings programs exclude Medicare and Medicaid, see the cost records.
What remains unknown
Questions people actually ask
Is there an FDA-approved GLP-1 patch?
Can semaglutide pass through skin at all?
What is in the GLP-1 patches sold online?
Are these patches legal to sell as supplements?
Why would a patch not work when a nicotine patch does?
Do the microneedle trials mean a patch is coming?
How is this different from compounded semaglutide?
Keep reading
- What each GLP-1 patch brand says it contains — ten listings read and written down, one at a time, with the date each was read.
- The FDA letter its own drug search does not return — one federal letter about a patch, and the searches that never find it.
- The microneedle trial record — every registered trial of a peptide through skin, and how far each got.
- Ozempic patch: what Novo Nordisk actually makes — the brand-name question, answered from the FDA applications.
- The semaglutide evidence guide — approval status, sourced values and what the label actually specifies.
- The tirzepatide evidence guide — the same treatment for the dual-agonist molecule.
- How compounded GLP-1 drugs are regulated — the shortage determinations, the two compounding sections, and the dates each window closed.
- The regulatory tracker — a dated changelog of FDA activity across every compound on this site.
Sources
How we checked these details
Reviewed 2026-08-12
Every count here came from a search we can restate, against a database anyone can reach, on a day we wrote down. Nothing here is a treatment recommendation and nothing here is a dose. The wider rules are in the sourcing methodology. If a number here has gone stale or a new trial has posted results, tell us at contact@healthspanledger.com and the correction gets logged with a date.
Where these figures come from
Beginner, everyday and emerging-topic guides
The FDA dates behind compounded tirzepatide
Whether compounded semaglutide is still legal
How strong the evidence is for tirzepatide
Where compounded GLP-1s stand today
How semaglutide differs from the rest of its class
Regulatory status, with the absence of an outcome recorded
Which compounds have a label and which do not